Treatment evolution in high-risk congenital diaphragmatic hernia: ten years\u27 experience with diaphragmatic agenesis. by Lally, Kevin P et al.
ORIGINAL ARTICLES
Treatment Evolution in High-Risk Congenital
Diaphragmatic Hernia
Ten Years’ Experience With Diaphragmatic Agenesis
By the Congenital Diaphragmatic Hernia Study Group
Objective: The objective of this study was to evaluate the impact of
newer therapies on the highest risk patients with congenital dia-
phragmatic hernia (CDH), those with agenesis of the diaphragm.
Summary Background Data: CDH remains a significant cause of
neonatal mortality. Many novel therapeutic interventions have been
used in these infants. Those children with large defects or agenesis
of the diaphragm have the highest mortality and morbidity.
Methods: Twenty centers from 5 countries collected data prospec-
tively on all liveborn infants with CDH over a 10-year period. The
treatment and outcomes in these patients were examined. Patients
were followed until death or hospital discharge.
Results: A total of 1569 patients with CDH were seen between
January 1995 and December 2004 in 20 centers. A total of 218
patients (14%) had diaphragmatic agenesis and underwent repair.
The overall survival for all patients was 68%, while survival was
54% in patients with agenesis. When patients with diaphragmatic
agenesis from the first 2 years were compared with similar patients
from the last 2 years, there was significantly less use of ECMO (75%
vs. 52%) and an increased use of inhaled nitric oxide (iNO) (30% vs.
80%). There was a trend toward improved survival in patients with
agenesis from 47% in the first 2 years to 59% in the last 2 years. The
survivors with diaphragmatic agenesis had prolonged hospital stays
compared with patients without agenesis (median, 68 vs. 30 days).
For the last 2 years of the study, 36% of the patients with agenesis
were discharged on tube feedings and 22% on oxygen therapy.
Conclusions: There has been a change in the management of infants
with CDH with less frequent use of ECMO and a greater use of iNO
in high-risk patients with a potential improvement in survival.
However, the mortality, hospital length of stay, and morbidity in
agenesis patients remain significant.
(Ann Surg 2006;244: 505–513)
Congenital diaphragmatic hernia (CDH) occurs in between1 in 2500 to 1 in 4000 live births.1,2 The first successful
repair in an infant under 24 hours of age was performed by
Gross in 1946.3 Since then, advances in neonatal anesthesia,
surgical techniques, and neonatal intensive care have allowed
sicker patients to survive transfer to tertiary hospitals. Mor-
tality for patients with CDH remained around 50% in the
1970s and 1980s.4,5 A significant number of newer therapies
for infants with respiratory failure became widely available in
the late 1980s and 1990s. These therapies included fetal inter-
vention, extracorporeal membrane oxygenation (ECMO), high
frequency oscillatory ventilation (HFOV), exogenous surfac-
tant, and inhaled nitric oxide (iNO). Application of these
newer therapies to infants with CDH has been based on
anecdotal case reports and retrospective reviews. While sur-
vival to hospital discharge appears to have improved, some
authors dispute these conclusions.6,7 Indeed, some of the
above-mentioned therapies, such as hyperventilation and fetal
therapy, have either not been proven beneficial or have been
shown to be harmful.8–10
While CDH has been viewed by some as a homoge-
neous disease process, there are clear differences in outcomes
between certain groups of patients. Infants with larger defects
have been shown to have a worse survival compared with
those with smaller defects11,12 It has been difficult to dem-
onstrate differences in outcome as the anomaly is uncommon
and any single center cannot accrue enough high-risk patients
to draw meaningful conclusions. The purpose of this study is
to evaluate outcomes and management changes over a 10-
year period in high-risk infants with CDH using a large,
multicenter database.
METHODS
The Congenital Diaphragmatic Hernia Study Group
(CDHSG) was formed in 1995 to compile data on liveborn
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babies with CDH at participating institutions with the goal of
assessing therapies and improving outcomes. The CDH Study
Group consists of tertiary referral centers that voluntarily
provide data to a central registry (Appendix). Data on all
infants with CDH who are born at or transferred to a partic-
ipating center are entered into the database. Data were col-
lected prospectively on all liveborn patients with CDH be-
tween January 1995 and December 2004 in participating
hospitals. Information on delivery and subsequent hospital
care (including surgery where applicable) until death or
hospital discharge was collected. Institutions were included
in this analysis if they had at least 10 consecutive years of
data submission. The data from the registry forms were
entered into a Microsoft Access database and were cross-
checked against the original forms. Patient demographics,
birth information, Apgar scores, treatments received, size of
the defects, and outcome were recorded. Therapeutic inter-
ventions including the use of ECMO, iNO, ventilatory strat-
egy (ie, permissive hypercapnea, hyperoxia, hyperventilation,
etc), surfactant, intravenous vasodilators, neuromuscular
blockade, and sedation were recorded.
The size of the diaphragm defect was determined by the
surgeon at the time of repair and coded as “agenesis” if the
entire diaphragm or most of the diaphragm was absent (based
on surgeons’ reports and/or operative notes with findings of
“absent or missing rim of diaphragm” or repair requiring
“suturing the patch to the ribs anteriorly and posteriorly”).
All patients with diaphragm agenesis required a patch to
repair the defect. In those patients without agenesis, either the
defect could be repaired primarily or a patch was required to
close the defect. A fourth group of patients never underwent
operation; most had a combination of either severe other
anomalies or were thought to have fatal pulmonary hypopla-
sia. Since this group has been shown to have the highest risk
of death, patients coded as diaphragm agenesis were com-
pared with the remainder of the patients who underwent
operation.
Statistical Analysis
Death prior to hospital discharge was the primary
outcome variable. The length of stay in the hospital and
duration of mechanical ventilation were secondary outcomes.
In an effort to determine if there had been a significant change
in management from the start of the registry, data from the
first 2 years were grouped and compared with the last 2 years
to compare outcome and types of therapies used. These data
were analyzed using a 2 analysis or unpaired t test where
appropriate. A P value of 0.05 was considered significant.
Patients who did not undergo repair were not included in the
final analysis.
The CDHSG registry was approved by the University
of Texas–Houston Institutional Review Board. Participating
centers filed a Waiver of Consent for data submission or
signed a Data Use Agreement for a Limited Data Set. The
analyses were conducted using the NCSS (version NCSS
2004; March 2004; NCSS, Kaysville, UT) statistical software
package.
RESULTS
Between 1995 and 2004, a total of 3278 patients were
entered in the registry from 90 centers. To determine changes
over time, we only used the data from centers who had
continuously submitted information for the entire 10-year
time period. There were 20 centers that met these criteria, and
they contributed 1569 patients to the database. Demographic
data for these patients are shown in Table 1. The overall
survival for all patients was 68%.
A total of 280 patients (18%) never underwent surgical
repair and all died; 67 of the nonrepaired patients (24%) were
noted to have severe associated anomalies (major cardiac,
syndromal, or chromosomal). The rest of the patients were
thought to have fatal pulmonary hypoplasia based on hemo-
dynamic instability or blood gas values.
During this time period, 1247 patients underwent repair
and had the defect size measured. There were 218 patients
coded as having agenesis of the diaphragm. The survival to
hospital discharge for this group was markedly lower than
that of the 1029 patients without agenesis who underwent
repair (54% vs. 89%, (P  0.001) (Table 2).
When analyzing the agenesis patients alone, there was
a significant change in management over the 10 years of this
study (Table 3). There was a significant decrease in the use
of ECMO from 75% in the first 2 years to 52% of patients in
the last 2 years. Conversely, there was a notable increase in
the use of iNO to where 80% of patients with agenesis were
treated with iNO in the last 2 years of the study compared
with 30% in the first 2 years. Data regarding the primary
respiratory strategy were not recorded until 2001 and were
therefore not available for the first years of the study; how-
TABLE 1. Demographic Data for the Patients
Database
Patients With
Agenesis
Patients Without
Agenesis
Inborn no. (%) of patients 589 (38) 112 (51) 327 (32)
Male no. (%) of patients 943 (60) 138 (64) 625 (61)
Prenatal diagnosis no. (%) of patients 798 (51) 141 (65) 442 (43)
Left-sided CDH no. (%) of patients 1256 (80) 173 (79) 851 (83)
Cardiac anomaly no. (%) of patients 216 (14) 23 (11) 113 (11)
Chromosomal anomaly/syndrome no. (%) of patients 71 (5) 9 (4) 28 (3)
Birth weight (kg) (mean  SD) 2.98  0.66 2.99  0.60 3.08  0.60
EGA at birth (wk) (mean  SD) 37.80  2.50 37.86  1.94 38.13  2.23
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ever, by the last 2 years of this study, permissive hypercapnea
had become the most widely used ventilation goal, with over
90% of patients having this as their strategy for ventilation.
There was a significant decrease in the use of hyperoxia and
induced alkalosis as a management strategy over the course
of the study (P  0.01) with no change in other management
strategies (Table 3). There was a trend toward improved
survival in the last 2 years of the study versus the first 2
years. Survival improved from 47% to 59% in patients with
agenesis, although this did not reach statistical significance
(P  0.24).
Morbidity in infants with CDH was high, but infants
with agenesis had significantly greater morbidity when com-
pared with the overall CDH population. As shown in Table 3,
the median length of hospital stay for survivors with agenesis
was much longer than for patients without agenesis. Some
type of delayed closure of the abdomen, such as creation of a
ventral hernia or patch abdominoplasty, was more commonly
used in the patients with agenesis. Gastroesophageal reflux
was also more prevalent in the patients with agenesis (Table
2). Similarly, the patients with agenesis had a significantly
higher rate of being discharged while still requiring tube
feeding as well as home oxygen.
DISCUSSION
CDH remains a significant cause of death in the new-
born. In the past, survival rates for liveborn infants with CDH
were often quoted in the 50% range, but as noted in this
report, survival appears to have improved.13,14 This apparent
increase in survival may be due to several causes, which may
include newer therapies to support infants with respiratory
failure that have been introduced in the past 2 decades. These
therapies include ECMO, the use of exogenous surfactant,
iNO, and high-frequency ventilation. Since infants with CDH
often have severe respiratory failure, most of the therapies
were rapidly adopted without the support of well-conducted
trials. However, subsequent reports suggest that some of
TABLE 2. Outcomes in Patients With Diaphragm Agenesis Compared With Patients
Without Diaphragm Agenesis
Patients With
Agenesis
Patients Without
Agenesis P
Mortality no. (%) of patients 100 (46) 109 (11) 0.001
ECMO no. (%) of patients 137 (63) 236 (23) 0.001
iNO no. (%) of patients 143 (68) 292 (30) 0.001
Delayed closure of abdomen no. (%) of patients 44 (22) 76 (9) 0.001
On O2 at 30 days* no. (%) of patients 76 (76) 209 (26) 0.001
On O2 at discharge* no. (%) of patients 39 (43) 94 (12) 0.001
Gavage feeds at discharge* no. (%) of patients 47 (51) 188 (25) 0.001
Gastroesophageal reflux* no. (%) of patients 70 (72) 309 (41) 0.001
Length of ventilation (days) (median)* 28 12 0.001
Length of hospital stay (days) (median)* 68 30 0.001
*These values were calculated on infants who survived to discharge home from the tertiary center.
TABLE 3. Outcome in Patients With Diaphragm Agenesis: 1995–1996 Versus
2003–2004
1995–1996 2003–2004 P
Mortality 19 (53) 26 (41) 0.241
ECMO no. (%) 27 (75) 33 (52) 0.022
iNO no. (%) 9 (29) 51 (80) 0.001
Hyperoxia no. (%) 8 (30) 4 (6) 0.003
Induced alkalosis no. (%) 15 (50) 11 (17) 0.001
Surfactant no. (%) 13 (35) 25 (39) 0.770
Intravenous vasodilators no. (%) 7 (24) 14 (22) 0.810
Vasopressors no. (%) 29 (83) 57 (89) 0.382
Sedation no. (%) 34 (100) 61 (95) 0.220
Neuromuscular blockade no. (%) 26 (81) 53 (83) 0.850
On O2 at 30 days* no. (%) 10 (67) 21 (64) 0.839
On O2 at discharge* no. (%) 3 (27) 7 (22) 0.715
Gavage feeds at discharge* no. (%) 8 (62) 12 (36) 0.121
Length of ventilation (days) (median)* 27 21 0.274
Length of hospital stay (days) (median)* 58 57 0.972
*These values were calculated on infants who survived to discharge home from the tertiary center.
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these therapies may have no proven benefit or may actually
be harmful when compared with “standard” interventions.
Examples include the previously mentioned widespread
adoption of hyperventilation for infants with CDH, which has
been shown to worsen survival, and the use of exogenous
surfactant, which has not been shown to be efficacious.10,15,16
An essential issue in evaluating outcome data in pa-
tients with CDH is the size of the hernia defect. This study
and others have shown that the size of the diaphragmatic
defect correlates well with survival as well as morbidity in
liveborn infants with CDH.11 While defect size is likely a
marker for the degree of pulmonary hypoplasia, it may also
correlate with the severity of pulmonary hypertension.
When evaluating those patients with large defects or
agenesis of the diaphragm there has been a trend to improved
survival, but the outcome remains poor. Since these patients
are the sickest of the population of infants with CDH, it is not
surprising that some of the advanced therapies are more
frequently used in this group of patients. ECMO is one
example of the application of advanced therapies without
clear evidence of benefit.17 The initial use of ECMO for
infants with CDH was often in patients with severe baro-
trauma, while currently, it is used primarily to assist in
preoperative stabilization and avoid ventilator induced lung
injury. Despite a decline in ECMO utilization in the high-risk
patient, over half of these infants were still managed with
ECMO during the last 2 years of the study. While it is
possible to place an infant with CDH and fatal pulmonary
hypoplasia on ECMO immediately upon delivery, there may
be no therapeutic options available to reverse the problem,
which is pulmonary hypoplasia. ECMO is best used as a
supportive therapy for cardiopulmonary failure until this can
be reversed or corrected. If an infant has fatal pulmonary
hypoplasia, there are no available proven therapeutic options
beyond lung transplantation, and there are no good metrics to
accurately predict the degree of pulmonary hypoplasia today.
The appropriate role for ECMO in these patients remains
unclear.18
When iNO has been used in the newborn with respira-
tory failure as a rescue therapy, it has been shown to be useful
in several randomized trials.19–21 Analysis of the subgroup of
CDH patients in these trials, however, has failed to show
benefit when used after the development of hypoxemic respi-
ratory failure.22 Despite these data, the majority of high-risk
CDH patients are being treated with iNO, with a marked
increase in utilization in the past few years. While the
indications and method of use were not captured in the
registry form, it is likely that the current use of iNO repre-
sents a different strategy than that evaluated during the
clinical trials. Increasingly, iNO has been used early as an
adjunct to manage the pulmonary hypertension and right
heart dysfunction commonly seen in patients with CDH as
opposed to being used as a rescue therapy to avoid ECMO
support.23 While it is now clearly a routine therapy in the
high-risk CDH patient, there are no well designed trials to
demonstrate optimal use of iNO in this population.
The CDH Registry was formed to allow collection and
analysis of data on treatment and outcomes of infants with
CDH from a large number of centers. While registries have
proven to be a good way to collect information on various
disorders, care should be taken in interpreting the data. The
database is observational and conclusions about therapies
should be made cautiously. The data are collected from
institutions that differ significantly in their patient referral
base and their criteria for accepting an infant with CDH for
admission. Criteria for “nonsalvageable” patients vary be-
tween centers and some patients in the repaired group in one
center may not have undergone operation in another. Many
infants with severe cardiac and chromosomal anomalies did
not undergo repair making the true impact of these factors
difficult to determine. There are also variations in surgical
practice that determine whether a patch is used. Similarly, the
definition of agenesis is likely to vary somewhat between
centers.
In addition to the high mortality, infants with CDH
have significant in-hospital morbidity and many are dis-
charged home requiring considerable further care. The length
of stay in the hospital for patients with agenesis is quite long,
with over half of the patients staying over 60 days. Impor-
tantly, these data only represent outcome to hospital transfer
or discharge; both long-term mortality and morbidity are
likely to be worse.24,25 As survival for these high-risk infants
improves, many will require careful long-term follow-up for
hernia recurrence, hearing deficits, and other problems.26,27
CONCLUSION
Infants with CDH and diaphragm agenesis continue to
have a significant mortality rate despite the application of
advanced therapies. Use of these advanced therapies such as
ECMO and iNO has changed notably over the past decade,
but in-hospital morbidity has remained high. As survival of
these patients improves, a focus on long-term issues will
become increasingly important.
APPENDIX. Members of the CDH Study Group Registry
Hospital City State/Province Country
Arnold Palmer Hospital For Women and Children* Orlando FL United States
Astrid Lindgren Stockholm Sweden
Cardinal Glennon Children’s Hospital St. Louis MO United States
Cedars Sinai Medical Center Los Angeles CA United States
(Continued )
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APPENDIX. (Continued )
Hospital City State/Province Country
Central Hospital Aichi Prefectural Colony Kasugai Aichi Japan
Children’s Hospital at Carolinas Medical Center* Charlotte NC United States
Children’s Hospital Boston Boston MA United States
Children’s Hospital of Akron* Akron OH United States
Children’s Hospital of Alabama Birmingham AL United States
Children’s Hospital of Austin Austin TX United States
Children’s Hospital of Buffalo Buffalo NY United States
Children’s Hospital of Illinois Peoria IL United States
Children’s Hospital of Los Angeles Los Angeles CA United States
Children’s Hospital of Michigan Detroit MI United States
Children’s Hospital of Minneapolis* Minneapolis MN United States
Children’s Hospital of Oakland Oakland CA United States
Children’s Hospital of Oklahoma* Oklahoma City OK United States
Children’s Hospital of Philadelphia Philadelphia PA United States
Children’s Hospital of Wisconsin* Milwaukee WI United States
Children’s Mercy Hospital Overland Park KS United States
Children’s National Medical Center Washington DC United States
Cincinnati Children’s Hospital Medical Center Cincinnati OH United States
Cleveland Clinic Foundation- Children’s Hospital Cleveland OH United States
Columbus Children’s Hospital Columbus OH United States
Cook Children’s Medical Center Ft. Worth TX United States
DeVos Children’s Hospital Grand Rapids MI United States
Duke University Medical Center Durham NC United States
Emory University* Atlanta GA United States
Freie Universitat Berlin Berlin Germany
Hasbro Children’s Hospital Providence RI United States
Hershey Medical Center Hershey PA United States
James Whitcomb Riley Children’s Hospital Indianapolis IN United States
Kosair Children’s Hospital* Louisville KY United States
Legacy Emanuel Children’s Hospital* Portland OR United States
Loma Linda University Children’s Hospital Loma Linda CA United States
Lucile Salter Packard Children’s Hospital* Palo Alto CA United States
Lutheran General Hospital Park Ridge IL United States
Massachusetts General Hospital Boston MA United States
Mattel Children’s Hospital at UCLA Los Angeles CA United States
Mayo Clinic Rochester MN United States
Medical College of Georgia* Augusta GA United States
Medical College of Virginia Richmond VA United States
Medical University of South Carolina Charleston SC United States
Memorial Hermann Children’s Hospital* Houston TX United States
Miami Valley Hospital Dayton OH United States
National Center for Child Health and Development Tokyo Japan
North Carolina Baptist Hospital Winston-Salem NC United States
Osaka Medical Center for Maternal and Child Health Izumi Osaka Japan
Osaka University Graduate School of Medicine Suita Osaka Japan
Ospedali Pediatrico Bambino Gesu Rome Italy
Ospedali Riuniti Bergamo* Bergamo Italy
Phoenix Children’s Hospital Phoenix AZ United States
Primary Children’s Hospital Salt Lake City UT United States
Rainbow Babies and Children Hospital Cleveland OH United States
Rockford Memorial Children’s Hospital Rockford IL United States
Royal Alexandra Hospital Edmonton Alberta Canada
Royal Children’s Hospital* Parkville Victoria Australia
(Continued )
*Centers used in this report.
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Discussions
DR. CHARLES J. STOLAR (NEW YORK, NEW YORK): Early
this morning we heard Dr. Warshaw comment that most
surgical challenges can be solved. Diaphragmatic hernia,
however, remains a significant neonatal challenge, which is
an important subset of patients that do succumb to this
disease. Defining this population either antenatally or post-
natally continues to be a very vexing challenge.
The good news is that individual neonatal centers, as
you allowed, Dr. Lally, such as those in New York, Boston,
Ann Arbor, Gainesville and others are now reporting single
institution survivals in large series between 80% and 90% and
were clearly improving morbidity. I think we are all finally
beginning to do better than, if that is possible.
Dr. Lally to his credit has motivated a lot of people to
amass a lot of information from a lot of diaphragmatic hernia
patients from a lot of neonatal centers in an effort to learn
from a collective experience. He is to be congratulated for
taking the initiative virtually single-handedly, along with his
wife, and following through on it.
He has told us that congenital diaphragmatic hernia is
indeed a heterogeneous disease but in the collective experi-
ence agenesis diaphragm remains associated with a poorer
prognosis than it might be if the diaphragm were wholly
there, and that over time there has been a coincidental
increase in the use of inhaled nitric oxide, changing respira-
tory care strategies, specifically the use of hyperventilation
and the avoidance of hyperventilation with reduced alkalosis,
also a decreased use of ECMO. Of interest in your aggregate,
survival of 68% is telling in that often-quoted mortality rates
for diaphragmatic hernias is often in excess of 68% as
justification for fetal intervention.
I would like to ask your views on some general and
some specific issues, Dr. Lally.
In general are you concerned about the heterogeneity of
the data and the impact on your observations? For example, the
wide range of respiratory care strategies that were used on this
population. For example, the range of individuals making treat-
ment decisions. Although we surgeons like to be see ourselves
as wholly responsible for neonates, the fact of the matter is
that taking care of a newborn in a modern neonatal intensive
care unit is a collaborative experience. I am also worried
about the range of indications for specific treatments such as
ECMO, such as nitric oxide, such as oscillating ventilation
and the like.
My specific questions, however, I would like to you
comment specifically on the following. Although you do pay
homage to the use of persistent hypercapnia and spontaneous
respiration, I come from the institution that first described this
in a paper written by Virginia Ephart and Stan James in 1975,
and this strategy specifically forbids the use of muscle relax-
ants and muscle paralysis. But I note in the data in the
manuscript that 80% to 83% of the patients had muscle
paralysis. And while I understand that not everybody agrees
to the same definition of hyperventilation due to alkalosis,
this is experience as the strategy was originally described.
I am concerned about the indications for inhaled nitric
oxide because in these several multicenter clinical trials
inhaled nitric oxide is a very effective agent for prematurity,
for idiopathic pulmonary hypertension. The one diagnosis for
which inhaled nitric oxide has never been systematically
shown to work is congenital diaphragmatic hernia, and I
wonder if its broad applications just spill over from an
experience with the premature baby.
I observed in your manuscript report that 12% to 43%
of these patients went home on oxygen and a significant
number are also on oxygen after 30 days. Many of us
consider this prima facie evidence of either bronchial pulmo-
nary dysplasia or persistent pulmonary hypertension. To what
extent is this really patient disease and to what extent is it
iatrogenic disease?
DR. KEVIN P. LALLY (HOUSTON, TEXAS): Regarding your
concerns over the heterogeneity of the data and the range of
indications, I think this is a reality of practice. These data
represent 20 centers but the entire study group represents about
55 active centers today. This is just what we are dealing with.
It is possible in a single institution to get one person or
several people managing a patient in the exact same fashion.
However, this becomes difficult to translate to many other
institutions. In an ideal world you would have a protocol-
based, evidence-based method of approaching these patients.
Even in my own institution, with a printed, agreed-upon,
standardized approach to how we are going to manage the
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patient, I can still come in at 7:00 in the morning and go,
“What went on last night?”
The Columbia version of permissive hypercapnia is
obviously not widely embraced by everybody around the
world. And I think that we need to get to the point, which we
are evolving to but it will take time, to when we report our
data where we are talking apples and apples. I cannot inter-
pret individual center data because I don’t know how many
high risk patients exist in an individual center. And it is
surprisingly variable. In the registry, it ranges from 5% to
35% of centers that manage patients that have agenesis,
which can have a huge impact on overall survival. So until we
get to the point we are comparing apples and apples, I don’t
know. But there are several centers that have and identical
survival to Columbia that use neuromuscular blockade but
they maybe have a different type of patient.
The indications for nitric oxide have been changing.
Every randomized trial of inhaled NO show no benefit in
CDH. All of them are designed as a rescue strategy for
avoidance of ECMO and improving survival when used early
in patients in respiratory failure. Most likely the current use
of nitric oxide is in a different strategy altogether. Much like
there has been an evolution in ECMO from a rescue strategy
to an early stabilization strategy, the same is true with NO. I
think that people generally avoid nitric oxide as a rescue
strategy but use it much more in the management of cardio-
vascular failure and right heart failure in the high risk pa-
tients. It is only used in about 25% of the non-agenesis
patients, so it is not applied to all patients with diaphrag-
matic hernia.
And lastly, the home oxygen patients—again, it is an
observational database. I suspect that there is a subgroup of
babies who still have significant iatrogenic lung disease, but
some centers will frequently send patients home on oxygen
with very little indication.
DR. KEITH GEORGESON (BIRMINGHAM, ALABAMA): Just a
couple of questions. First of all, congratulations on the
tenacity to hang in there for over 10 years to get this data.
I wonder if you can break down the difference between
survival of patients that are patch repaired and those that are
primarily repaired.
Also, I would like to you speculate on the impact of
therapeutic abortion. In some other papers, therapeutic abor-
tion has been shown to be one of the reasons why our survival
has improved, and I wonder what your thoughts are with this
database.
Lastly, in our center now ECMO is primarily used as a
last resort and most of these patients are dying. So I am a little
surprised that the ECMO rate is still over 50%.
DR. KEVIN P. LALLY (HOUSTON, TEXAS): Regarding the
survival for patch repair versus primary repair, we can actu-
ally grade these further by even large defects versus those
defects with patch. We are working towards using that as a
potential postoperative staging system that would enable us to
compare patients with the same level of severity. The infants
who undergo primary repair of the diaphragm, which is about
50% of the operative patients, have a 95%-plus survival. And
I think that is going to ultimately be important to us because
throwing all these advanced therapies at that low-risk popu-
lation is probably not a good idea.
Regarding the impact of elective termination of preg-
nancy, I think that it probably does impact outcome. How-
ever, I don’t think that those are necessarily terminated on the
basis of appropriate prenatal stratification. So I think that they
are terminating pregnancies on the basis of diagnosis alone,
hence it probably includes both high and low risk groups.
This represents only liveborn infants so I am not sure that it
impacts on the data set per se.
As far as ECMO, very clearly, it is applied today as a
stabilization device as opposed to rescue therapy. There is a
whole list of other questions now as we evolve our use of
ECMO and avoid iatrogenic lung injury, what is its benefit in
these patients? And I remain very unclear about what EC-
MO’s role is. A few patients, I am sure, are alive that
wouldn’t be without it, but there are several others where that
is unclear.
DR. GEORGE W. HOLCOMB, III (KANSAS CITY, MISSOURI):
In looking over the last ten years of data have you noticed an
evolution of the type of patch that is used when a patch is
required? And do you have any data to suggest that one type
of patch has a lower recurrence rate than another?
DR. KEVIN P. LALLY (HOUSTON, TEXAS): We asked patch
type in the first version of registry, and since it was over-
whelming PTFE we quit asking. We may actually dial it into
Version 3 of the registry again. But I think if you look
specifically at the subgroup of agenesis patients it is impos-
sible not to expect recurrence because chest wall has to grow
as does the patient. And the issue of whether some other type
of material is optimal or not, I don’t know.
DR. THOMAS F. TRACY, JR. (PROVIDENCE, RHODE ISLAND):
Dr. Lally, congratulations to the Diaphragmatic Hernia Study
Group especially for giving us the reality of the mortality
figures. I have had a sense that we have come close to hubris
because of the outstanding work that has been done at
Columbia and subsequently Florida with the other papers that
Dr. Stolar mentioned about outcomes.
However, the specter of fetal intervention is still alive.
There is a current study that is going on through Eurofetus as
a trial of late tracheal occlusion that may be more sensitive
and specific for adequate prenatal lung development. You
focused on a group of diaphragmatic agenesis patients, which
can now be defined prenatally. Does your study look at any
other parameters that we can look to besides other anatomical
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indicators similar to lung to head circumference ratios or
anything else that would help refine that study to target a
subset of fetal patients that would be best suited for this trial?
DR. KEVIN P. LALLY (HOUSTON, TEXAS): No. But we are
hoping that a subset of the next group of the registry, because
it has to be in consent form, is to dial in a prenatal component
to attach to the postnatal outcome. This is a post-delivery
outcome. There are no multi-centered, validated accurate
predictors for outcome in prenatally diagnosed CDH. The
group in Europe talks about patients with both the liver up in
the chest and a low LHR and combined to come up with some
outcomes for this. I think there is a subgroup of babies with
CDH that we do not have an answer for today.
So I don’t know if it is the specter of fetal intervention
as much as we need to accurately and appropriately define a
subgroup of babies where it’s use can be more appropriately
studies. We are clearly not there today.
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